Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20, Venetoclax and Azacitidine in AML
NCT05001828Phase 1Active, not recruiting
- Sponsor
- Polaris Group
- Start
- Apr 2022
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pegargiminase in acute myeloid leukemia (AML) (2 arms), sponsored by Polaris Group. Primary endpoint: Recommended Phase 2 Dose at 6 months. Started Apr 2022; status: active, not recruiting.
02
Drugs
Pegargiminase
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05001828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001828.